Compare WTRG & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTRG | CYTK |
|---|---|---|
| Founded | 1901 | 1997 |
| Country | United States | United States |
| Employees | 1615 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 10.7B |
| IPO Year | 1994 | 2004 |
| Metric | WTRG | CYTK |
|---|---|---|
| Price | $40.92 | $79.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 19 |
| Target Price | $43.50 | ★ $89.26 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | ★ 1.38 | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $2,474,615,000.00 | $13,368,000.00 |
| Revenue This Year | $5.07 | $7.37 |
| Revenue Next Year | $7.31 | $310.19 |
| P/E Ratio | $35.14 | ★ N/A |
| Revenue Growth | ★ 18.62 | N/A |
| 52 Week Low | $36.11 | $35.22 |
| 52 Week High | $42.37 | $88.31 |
| Indicator | WTRG | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 57.90 | 48.55 |
| Support Level | $37.88 | $73.34 |
| Resistance Level | $41.61 | $79.66 |
| Average True Range (ATR) | 0.78 | 2.31 |
| MACD | 0.04 | 0.19 |
| Stochastic Oscillator | 82.86 | 55.81 |
Essential Utilities is a Pennsylvania-based holding company for US water, wastewater, and natural gas distribution utilities. The company's water business serves 3 million people in eight states. Its largest service territory is in Pennsylvania, primarily suburban Philadelphia. Its Peoples subsidiary serves more than 740,000 gas distribution customers in Pennsylvania and Kentucky. It completed the sale of its West Virginia gas utility and the bulk of its nonregulated assets in 2024. Essential shareholders would own a 31% stake in American Water Works if the proposed all-stock merger closes in 2027.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.